Novartis (NOVN.SW) stock: key figures, P/E, revenue and dividend
Health Care · Switzerland · ISIN CH0012005267
Novartis financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 51.72 bn USD | 57.13 bn USD |
| Gross profit | 36.23 bn USD | 42.14 bn USD |
| Operating income | 16.32 bn USD | 19.01 bn USD |
| EBIT | 13.55 bn USD | 17.49 bn USD |
| Net income | 11.94 bn USD | 14.65 bn USD |
| Diluted EPS – continuing operations | 5.55 USD | 7.47 USD |
Full history since 1994, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Novartis
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
More stocks
- Shell PLC (SHEL.L)
- Palo Alto Networks (PANW)
- Shell PLC ADR (SHEL)
- Banque Cantonale de Geneve (BCGE.SW)
- Home Depot (The) (HD)
- Netflix (NFLX)
- Morgan Stanley (MS)
- Novartis AG ADR (NVS)
- Royal Bank of Canada (RY.TO)
- Alibaba Group Holding Ltd (BABA)
- Texas Instruments Incorporated (TXN.MX)
- SAP (SAP.DE)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.